Luteolin treatment in a dose-dependent manner inhibited EMT, protein expression of MMPs (i.e., MMP2/7/9), and STAT3 signaling, as well as decreased the invasiveness of pancreatic cancer cells [136]. Here, MMP2 is linked to familial pancreatic carcinoma.